STOK Stock Forecast 2025-2026
Distance to STOK Price Targets
STOK Price Momentum
10 Quality Stocks Worth Considering Now
Researching Stoke (STOK) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on STOK and similar high-potential opportunities.
Latest STOK Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, STOK has a bullish consensus with a median price target of $21.00 (ranging from $15.00 to $47.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $7.40, the median forecast implies a 183.8% upside. This outlook is supported by 9 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andrew Fein at HC Wainwright & Co., projecting a 535.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STOK Analyst Ratings
STOK Price Target Range
Latest STOK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STOK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 19, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $47.00 |
| Mar 19, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $24.00 |
| Mar 18, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| Feb 19, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $24.00 |
| Feb 18, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $47.00 |
| Feb 18, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| Jan 8, 2025 | Needham | Joseph Stringer | Buy | Maintains | $22.00 |
| Jan 8, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $35.00 |
| Dec 20, 2024 | Chardan Capital | Rudy Li | Buy | Initiates | $24.00 |
| Dec 10, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Nov 6, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $35.00 |
| Sep 11, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $35.00 |
| Aug 8, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| Jul 11, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $17.00 |
| Jun 28, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| May 7, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $20.00 |
| May 7, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $35.00 |
| May 6, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| Apr 11, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
Stoke Therapeutics Inc. (STOK) Competitors
The following stocks are similar to Stoke based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Stoke Therapeutics Inc. (STOK) Financial Data
Stoke Therapeutics Inc. has a market capitalization of $400.17M with a P/E ratio of -4.5x. The company generates $36.56M in trailing twelve-month revenue with a -243.4% profit margin.
Revenue growth is +707.1% quarter-over-quarter, while maintaining an operating margin of -60.4% and return on equity of -45.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Stoke Therapeutics Inc. (STOK) Business Model
About Stoke Therapeutics Inc.
Develops RNA-based treatments for genetic diseases.
Stoke Therapeutics utilizes its proprietary TANGO platform to create therapies that enhance protein production in target tissues, specifically focusing on rare genetic disorders. The company generates revenue through partnerships, licensing agreements, and potentially through the commercialization of its innovative treatments for conditions like Dravet syndrome.
By targeting genetic diseases that affect the central nervous system and liver, Stoke Therapeutics positions itself as a leader in the biopharmaceutical sector, addressing significant unmet medical needs and opening new avenues for RNA-based therapeutics.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
128
CEO
Mr. Ian F. Smith A.C.A., C.P.A.
Country
United States
IPO Year
2019
Website
www.stoketherapeutics.comStoke Therapeutics Inc. (STOK) Latest News & Analysis
Stoke Therapeutics (STOK) shares declined after the announcement of CEO Dr. Edward Kaye's resignation.
CEO departures can signal instability or shifts in company strategy, potentially impacting investor confidence and stock performance.
Stoke Therapeutics Announces CEO Transition
9 days agoStoke Therapeutics' CEO, Edward M. Kaye, M.D., will step down on March 19, 2025. The company focuses on RNA medicine and has a lead treatment for Dravet syndrome.
Leadership changes can impact investor confidence and stock performance. Edward Kaye's departure may raise concerns about Stoke Therapeutics' strategic direction and future growth.
Stoke Therapeutics (Nasdaq: STOK) reported its 2024 financial results and updates on zorevunersen, a potential treatment for Dravet syndrome, marking recent milestone achievements.
Stoke Therapeutics' advancements in RNA medicine and financial results could impact its stock performance, reflecting the company's growth potential and market confidence in innovative treatments.
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
10 days agoStoke Therapeutics (STOK) is anticipated to potentially exceed earnings expectations in its upcoming report, highlighting key factors supporting this outlook.
Stoke Therapeutics' potential earnings beat could signal strong performance, impacting stock price and investor sentiment positively.
Stoke Therapeutics (STOK) reported a quarterly loss of $0.18 per share, beating the Zacks Consensus Estimate of $0.51 and improving from a loss of $0.60 per share a year earlier.
Stoke Therapeutics' smaller-than-expected loss signals improved financial performance, potentially boosting investor confidence and stock value.
Stoke Therapeutics will present at the TD Cowen Healthcare Conference on March 5, 2025, at 9:50 a.m. ET, and the Leerink Partners Healthcare Conference on March 10, 2025, at 10:40 a.m. ET.
Stoke Therapeutics' upcoming presentations at major healthcare conferences may attract investor attention, potentially influencing stock performance and market sentiment around its RNA medicine developments.
Frequently Asked Questions About STOK Stock
What is Stoke Therapeutics Inc.'s (STOK) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Stoke Therapeutics Inc. (STOK) has a median price target of $21.00. The highest price target is $47.00 and the lowest is $15.00.
Is STOK stock a good investment in 2025?
According to current analyst ratings, STOK has 9 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STOK stock?
Wall Street analysts predict STOK stock could reach $21.00 in the next 12 months. This represents a 183.8% increase from the current price of $7.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stoke Therapeutics Inc.'s business model?
Stoke Therapeutics utilizes its proprietary TANGO platform to create therapies that enhance protein production in target tissues, specifically focusing on rare genetic disorders. The company generates revenue through partnerships, licensing agreements, and potentially through the commercialization of its innovative treatments for conditions like Dravet syndrome.
What is the highest forecasted price for STOK Stoke Therapeutics Inc.?
The highest price target for STOK is $47.00 from Andrew Fein at HC Wainwright & Co., which represents a 535.1% increase from the current price of $7.40.
What is the lowest forecasted price for STOK Stoke Therapeutics Inc.?
The lowest price target for STOK is $15.00 from at , which represents a 102.7% increase from the current price of $7.40.
What is the overall STOK consensus from analysts for Stoke Therapeutics Inc.?
The overall analyst consensus for STOK is bullish. Out of 13 Wall Street analysts, 9 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $21.00.
How accurate are STOK stock price projections?
Stock price projections, including those for Stoke Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
